SCHEMBL1301424

SCHEMBL1301424

COc1nc2c(cc1NCc1cccc(Cl)c1)c(=O)c(C(=O)O)cn2C(CO)C(C)C

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 1/20 0.46
▸ PDE9A O76083 4/20 0.41
▸ APEX1 P27695 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ CD38 P28907 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ PDE10A Q9Y233 1/20 0.36
▸ PDE2A O00408 1/20 0.36
▸ RPS6KB1 P23443 2/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35
▸ CASR P41180 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ HCRTR1 O43613 1/20 0.35
▸ AKT1 P31749 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ MRGPRX4 Q96LA9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1301419 1.00 METTL3 (0.46) METTL3PDE9AAPEX1KMT2ACD38
SCHEMBL1301916 0.92 METTL3 (0.45) METTL3APEX1KMT2AMEN1MAPT
SCHEMBL1301914 0.92 METTL3 (0.45) METTL3APEX1KMT2AMEN1MAPT
SCHEMBL1300646 0.92 METTL3 (0.44) METTL3PDE9AKMT2ACD38L3MBTL1
SCHEMBL1300641 0.92 METTL3 (0.44) METTL3PDE9AKMT2ACD38L3MBTL1
SCHEMBL1300784 0.91 METTL3 (0.43) METTL3PDE9ACD38MAPT
SCHEMBL1300778 0.91 METTL3 (0.43) METTL3PDE9ACD38MAPT
SCHEMBL1301076 0.91 METTL3 (0.46) METTL3PDE9APDE10ARPS6KB1MAPT
SCHEMBL1301072 0.91 METTL3 (0.46) METTL3PDE9APDE10ARPS6KB1MAPT
SCHEMBL1301164 0.90 METTL3 (0.43) METTL3APEX1CD38RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885PDE9A 1229/4885APEX1 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback